ARCHIVES

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 8 | August 26, 2011

Download PDF Visit The Full Archive

Related Articles

Guest Editorial: Omics Checklist Done, Now Create Business Model For Tests

February 7, 2013

BRM Phase 1-2 Task Orders Awarded

November 21, 1980

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

In Brief: ‘WSJ” Articles Call Attention To Problems With Cancer Program Knipmeyer to Leave NCI

May 19, 1989

Concepts For Education Initiatives In Breast Ca Approved As RFA

July 9, 1993

Controversial Toxicology Protocol Is “Getting The Information We Need;” Additionally Revision Made

March 2, 1984